Processa Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
PCSA$1.95+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Expenses | ||
| Research and development expenses | $7,810,337 | $7,269,146 |
| General and administrative expenses | 6,178,168 | 4,782,060 |
| Operating Loss | (13,988,505) | (12,051,206) |
| Other Income (Expense) | ||
| Other income | 20,000 | - |
| Unrealized gain on digital assets at fair value | 295,180 | - |
| Interest and dividend income, net | 109,491 | 201,088 |
| Net Operating Loss Before Income Tax Benefit | (13,563,834) | (11,850,118) |
| Income Tax Benefit | - | - |
| Net Loss | $(13,563,834) | $(11,850,118) |
| Net Loss Per Common Share - Basic and Diluted | $(10.36) | $(96.78) |
| Weighted Average Common Shares Used to Compute | ||
| Net Loss Per Common Shares - Basic and Diluted | 1,309,271 | 122,438 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.